Combination of tocainide and quinidine for better tolerance and additive effects in patients with coronary artery disease

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The efficacy and tolerance of tocainide used alone and in combination with quinidine were studied in 20 patients with coronary artery disease and frequent (≥30/h) ventricular premature complexes. Holter electrocardiographic monitoring was performed at baseline and during therapy with tocainide alone, quinidine alone and a combination of tocainide and quinidine. During single drug therapy, the dose of tocainide was 1,680 ± 437 mg/day and that of quinidine was 1,340 ± 235 mg/day. During combination therapy, with smaller doses of tocainide (1,350 ± 394 mg/day) and quinidine (1,060 ± 268 mg/day) in many patients, no patient had side effects. At baseline before therapy, the mean ventricular premature complexes/h were 629 ± 567, couplets/h were 23.9 ± 29.7 and nonsustained ventricular tachycardias/24 h were 60.5 ± 152.2. Compared with baseline values (100%), the frequency of ventricular premature complexes was reduced to 33 ± 44% with quinidine, 39 ± 30% with tocainide and 10 ± 16% with combination therapy (p < 0.01 for combination versus quinidine or tocainide alone; p = NS for quinidine versus tocainide). Individually, an effective regimen (>83% reduction of ventricular premature complexes and abolition of nonsustained ventricular tachycardia) was found in 3 (15%) of 20 patients receiving tocainide alone, in 6 (30%) receivng quinidine alone and in 16 (80%) receiving combination therapy (p < 0.01 for tocainide versus combination, quinidine versus combination; p = NS for tocainide versus quinidine). Thus, the antiarrhythmic effects of quinidine and tocainide are additive. A combination of quinidine and tocainide in smaller and well tolerated doses may avoid dose-related side effects and is more effective than either drug used alone at higher doses. Therefore, when quinidine or tocainide is ineffective because dose-related side effects limit the maximal tolerated dose, combination therapy in smaller and tolerable doses may avoid side effects and may be more effective than either drug alone at the maximal tolerated dose.

Original languageEnglish (US)
Pages (from-to)1369-1374
Number of pages6
JournalJournal of the American College of Cardiology
Volume9
Issue number6
StatePublished - 1987

Fingerprint

Tocainide
Quinidine
Coronary Artery Disease
Ventricular Premature Complexes
Maximum Tolerated Dose
Ventricular Tachycardia
Therapeutics
Ambulatory Electrocardiography

ASJC Scopus subject areas

  • Nursing(all)

Cite this

@article{ba59f04b6a644ee7b67620dfb20dd287,
title = "Combination of tocainide and quinidine for better tolerance and additive effects in patients with coronary artery disease",
abstract = "The efficacy and tolerance of tocainide used alone and in combination with quinidine were studied in 20 patients with coronary artery disease and frequent (≥30/h) ventricular premature complexes. Holter electrocardiographic monitoring was performed at baseline and during therapy with tocainide alone, quinidine alone and a combination of tocainide and quinidine. During single drug therapy, the dose of tocainide was 1,680 ± 437 mg/day and that of quinidine was 1,340 ± 235 mg/day. During combination therapy, with smaller doses of tocainide (1,350 ± 394 mg/day) and quinidine (1,060 ± 268 mg/day) in many patients, no patient had side effects. At baseline before therapy, the mean ventricular premature complexes/h were 629 ± 567, couplets/h were 23.9 ± 29.7 and nonsustained ventricular tachycardias/24 h were 60.5 ± 152.2. Compared with baseline values (100{\%}), the frequency of ventricular premature complexes was reduced to 33 ± 44{\%} with quinidine, 39 ± 30{\%} with tocainide and 10 ± 16{\%} with combination therapy (p < 0.01 for combination versus quinidine or tocainide alone; p = NS for quinidine versus tocainide). Individually, an effective regimen (>83{\%} reduction of ventricular premature complexes and abolition of nonsustained ventricular tachycardia) was found in 3 (15{\%}) of 20 patients receiving tocainide alone, in 6 (30{\%}) receivng quinidine alone and in 16 (80{\%}) receiving combination therapy (p < 0.01 for tocainide versus combination, quinidine versus combination; p = NS for tocainide versus quinidine). Thus, the antiarrhythmic effects of quinidine and tocainide are additive. A combination of quinidine and tocainide in smaller and well tolerated doses may avoid dose-related side effects and is more effective than either drug used alone at higher doses. Therefore, when quinidine or tocainide is ineffective because dose-related side effects limit the maximal tolerated dose, combination therapy in smaller and tolerable doses may avoid side effects and may be more effective than either drug alone at the maximal tolerated dose.",
author = "Kim, {Soo G.} and Mercando, {A. D.} and Fisher, {John Devens}",
year = "1987",
language = "English (US)",
volume = "9",
pages = "1369--1374",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Combination of tocainide and quinidine for better tolerance and additive effects in patients with coronary artery disease

AU - Kim, Soo G.

AU - Mercando, A. D.

AU - Fisher, John Devens

PY - 1987

Y1 - 1987

N2 - The efficacy and tolerance of tocainide used alone and in combination with quinidine were studied in 20 patients with coronary artery disease and frequent (≥30/h) ventricular premature complexes. Holter electrocardiographic monitoring was performed at baseline and during therapy with tocainide alone, quinidine alone and a combination of tocainide and quinidine. During single drug therapy, the dose of tocainide was 1,680 ± 437 mg/day and that of quinidine was 1,340 ± 235 mg/day. During combination therapy, with smaller doses of tocainide (1,350 ± 394 mg/day) and quinidine (1,060 ± 268 mg/day) in many patients, no patient had side effects. At baseline before therapy, the mean ventricular premature complexes/h were 629 ± 567, couplets/h were 23.9 ± 29.7 and nonsustained ventricular tachycardias/24 h were 60.5 ± 152.2. Compared with baseline values (100%), the frequency of ventricular premature complexes was reduced to 33 ± 44% with quinidine, 39 ± 30% with tocainide and 10 ± 16% with combination therapy (p < 0.01 for combination versus quinidine or tocainide alone; p = NS for quinidine versus tocainide). Individually, an effective regimen (>83% reduction of ventricular premature complexes and abolition of nonsustained ventricular tachycardia) was found in 3 (15%) of 20 patients receiving tocainide alone, in 6 (30%) receivng quinidine alone and in 16 (80%) receiving combination therapy (p < 0.01 for tocainide versus combination, quinidine versus combination; p = NS for tocainide versus quinidine). Thus, the antiarrhythmic effects of quinidine and tocainide are additive. A combination of quinidine and tocainide in smaller and well tolerated doses may avoid dose-related side effects and is more effective than either drug used alone at higher doses. Therefore, when quinidine or tocainide is ineffective because dose-related side effects limit the maximal tolerated dose, combination therapy in smaller and tolerable doses may avoid side effects and may be more effective than either drug alone at the maximal tolerated dose.

AB - The efficacy and tolerance of tocainide used alone and in combination with quinidine were studied in 20 patients with coronary artery disease and frequent (≥30/h) ventricular premature complexes. Holter electrocardiographic monitoring was performed at baseline and during therapy with tocainide alone, quinidine alone and a combination of tocainide and quinidine. During single drug therapy, the dose of tocainide was 1,680 ± 437 mg/day and that of quinidine was 1,340 ± 235 mg/day. During combination therapy, with smaller doses of tocainide (1,350 ± 394 mg/day) and quinidine (1,060 ± 268 mg/day) in many patients, no patient had side effects. At baseline before therapy, the mean ventricular premature complexes/h were 629 ± 567, couplets/h were 23.9 ± 29.7 and nonsustained ventricular tachycardias/24 h were 60.5 ± 152.2. Compared with baseline values (100%), the frequency of ventricular premature complexes was reduced to 33 ± 44% with quinidine, 39 ± 30% with tocainide and 10 ± 16% with combination therapy (p < 0.01 for combination versus quinidine or tocainide alone; p = NS for quinidine versus tocainide). Individually, an effective regimen (>83% reduction of ventricular premature complexes and abolition of nonsustained ventricular tachycardia) was found in 3 (15%) of 20 patients receiving tocainide alone, in 6 (30%) receivng quinidine alone and in 16 (80%) receiving combination therapy (p < 0.01 for tocainide versus combination, quinidine versus combination; p = NS for tocainide versus quinidine). Thus, the antiarrhythmic effects of quinidine and tocainide are additive. A combination of quinidine and tocainide in smaller and well tolerated doses may avoid dose-related side effects and is more effective than either drug used alone at higher doses. Therefore, when quinidine or tocainide is ineffective because dose-related side effects limit the maximal tolerated dose, combination therapy in smaller and tolerable doses may avoid side effects and may be more effective than either drug alone at the maximal tolerated dose.

UR - http://www.scopus.com/inward/record.url?scp=0023216274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023216274&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 1369

EP - 1374

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 6

ER -